Totus Medicines utilizes AI/ML and DNA-encoded covalent library technology to discover small molecule drugs targeting previously undruggable disease pathways. Their platform enables high-throughput drug discovery, significantly increasing the speed and efficiency of developing therapeutics for advanced cancers and other serious conditions.
Funding
$107M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many disease targets, particularly in oncology, have been considered "undruggable" due to limitations in traditional drug discovery methods. This leaves a significant portion of potential therapeutic pathways unexplored, hindering the development of effective treatments for advanced cancers and other serious conditions.
Solution
Totus Medicines is developing small molecule drugs against previously undruggable disease pathways by using AI/ML and DNA-encoded covalent library technology. Their high-throughput platform enables the discovery of drugs at a greater volume, speed, and efficiency than traditional methods. Covalent molecules serve as a universal key to unlocking these targets for both non-covalent and covalent drug development. The company is creating a comprehensive catalog of drugs across the entire human genome, with an initial focus on poorly treated, advanced forms of cancer, including medicines for the most mutated oncogenes.
Target Audience
The primary target audience includes patients with advanced cancers and other serious conditions with limited treatment options, as well as pharmaceutical companies seeking to expand their drug development pipelines with novel therapeutics.
Features
- AI/ML-driven platform for identifying and validating novel drug targets.
- DNA-encoded covalent library technology for high-throughput screening of small molecule interactions.
- Covalent drug discovery approach to address traditionally undruggable targets.
- Development of both non-covalent and covalent drugs.
- Focus on oncology, with a pipeline of programs targeting advanced cancers.